Pentoxifylline for the treatment of nonalcoholic fatty liver disease: A meta-analysis of randomized double-blind, placebo-controlled studies

European Journal of Gastroenterology and Hepatology

Volumn 26, Issue 6, 2014, Pages 646-653

  Zeng, Tao ^a   Zhang, Cui Li ^a   Zhao, Xiu Lan ^a   Xie, Ke Qin ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

Meta analysis; nonalcoholic fatty liver disease; pentoxifylline; tumor necrosis factor

Indexed keywords

ADIPONECTIN; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; PENTOXIFYLLINE; TUMOR NECROSIS FACTOR ALPHA; AMINOTRANSFERASE; NONSTEROID ANTIINFLAMMATORY AGENT;

ABDOMINAL CRAMP; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLINDNESS; BLOATING; COCHRANE LIBRARY; COHORT ANALYSIS; DIARRHEA; DIET RESTRICTION; DIZZINESS; DRUG INDUCED HEADACHE; EMBASE; ENZYME ACTIVITY; FIBROSIS; HUMAN; INFLAMMATION; LIVER HISTOLOGY; MEDLINE; META ANALYSIS; NAUSEA; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); STEATOSIS; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; VOMITING; ANTAGONISTS AND INHIBITORS; BLOOD; DOUBLE BLIND PROCEDURE; NON-ALCOHOLIC FATTY LIVER DISEASE;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DOUBLE-BLIND METHOD; HUMANS; NON-ALCOHOLIC FATTY LIVER DISEASE; PENTOXIFYLLINE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TRANSAMINASES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84900451257     PISSN: 0954691X     EISSN: 14735687     Source Type: Journal    
DOI: 10.1097/MEG.0000000000000068     Document Type: Article

References (42)

1. pag 646-653 1 Ratziu V, Bellentani S, Cortez-Pinto H, Day C, Marchesini G. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol 2010; 53:372-384
2. Younossi ZM, Stepanova M, Afendy M, Fang Y, Younossi Y, Mir H, et al. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clin Gastroenterol Hepatol 2011; 9:524-530
3. Day CP. Clinical spectrum and therapy of non-alcoholic steatohepatitis. Dig Dis 2012; 30 (Suppl 1):69-73
4. Zhang Y, Baker SS, Baker RD, Zhu R, Zhu L. Systematic analysis of the gene expression in the livers of nonalcoholic steatohepatitis: implications on potential biomarkers and molecular pathological mechanism. PloS One 2012; 7:e51131
5. Mahady SE , George J. Management of nonalcoholic steatohepatitis: an evidence-based approach. Clin Liver Dis 2012; 16:631-645
6. Boettcher E, Csako G, Pucino F, Wesley R, Loomba R. Meta-analy sis: pioglitazone improves liver histology and fibrosis in patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2012; 35:66-75
7. Braunersreuther V, Viviani GL, Mach F, Montecucco F. Role of cytokines and chemokines in non-alcoholic fatty liver disease. World J Gastroenterol 2012; 18:727-735
8. Ruiz AG, Casafont F, Crespo J, Cayon A, Mayorga M, Estebanez A, et al. Lipopolysaccharide-binding protein plasma levels and liver TNF-alpha gene expression in obese patients: evidence for the potential role of endotoxin in the pathogenesis of non-alcoholic steatohepatitis. Obes Surg 2007; 17:1374-1 380
9. Bahcecioglu IH, Yalniz M, Ataseven H, Ilhan N, Ozercan IH, Seckin D, et al. Levels of serum hyaluronic acid, TNF-alpha and IL-8 in patients with nonalcoholic steatohepatitis. Hepatogastroentero logy 2005; 52: 1549-1553
10. Li Z, Yang S, Lin H, Huang J, Watkins PA, Moser AB, et al. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology 2003; 37:343-350
11. Koca SS, Bahcecioglu IH, Poy razoglu OK, Ozercan IH, Sahin K, Ustundag B. The treatment with antibody of TNF-alpha reduces the inflammation, necrosis and fibrosis in the non-alcoholic steatohepatitis induced by methionine-and choline-deficient diet. Inflammation 2008; 31:91-98
12. Crespo J, Cayon A, Fernandez-Gil P, Hernandez-Guerra M, Mayorga M, Dominguez-Diez A, et al. Gene expression of tumor necrosis factor alpha and TNF-receptors, p55 and p75 , in nonalcoholic steatohepatitis patients. Hepatology 2001; 34:1158-1163
13. Yalniz M, Bahcecioglu IH, Kuzu N, Celebi S, Ataseven H, Ustundag B, et al. Amelioration of steatohepatiti s with pentoxifylline in a novel nonalcoholic steatohepatitis model induced by high-fat diet. Dig Dis Sci 2007; 52: 2380-2386
14. Strieter RM, Remick DG,Ward PA, Spengler RN, Lynch JP III, Larrick J, et al. Cellular and molecular regulation of tumor necrosis factor-alpha production by pentoxifylline. Biochem Biophys Res Commun 1988; 155:1230-1236
15. Chae MK, Park SG, Song SO, Kang ES , Cha BS, Lee HC, et al. Pentoxifylline attenuates methionine-and choline-deficient-diet-induced steatohepatitis by suppressing TNF-alpha expression and endoplasmic reticulum stress. Exp Diabetes Res 2012; 2012:76256 5
16. Koppe SW, Sahai A, Malladi P, Whitington PF, Green RM. Pentoxifylline attenuates steatohepatitis induced by the methionine choline deficient diet. J Hepatol 2004; 41:592-598
17. Satapathy SK, Garg S, Chauhan R, Sakhuja P, Malhotra V, Sharma BC, et al. Beneficial effects of tumor necrosis factor-alpha inhibition by pentoxifylline on clinical, biochemical, and metabolic parameters of patie nts with nonalcoholic steatohepatitis. Am J Gastroenterol 2004; 99:1946-1952
18. Adams LA, Zein CO, Angulo P, Lindor KD. A pilot trial of pentoxifylline in nonalcoholic steatohepatitis. Am J Gastroenterol 2004; 99:2365-2368
19. Li W, Zheng L, Sheng C, Cheng X, Qing L, Qu S. Systematic review on the treatment of pentoxifylline in patients with non-alcoholic fatty liver disease. Lipids Health Dis 2011; 10:49
20. Jadad AR Moore RA Carroll D Jenkinson C Reynolds DJ Gavaghan DJ et al, Assessing the quality of reports of randomized clinical trials: is blindi ng necessary Control Clin Trials, 1996,17, 1-12.
21. Gu WJ, Wei CY, Yin RX. Antioxidant supplementation for the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: a meta-analys is of randomized controlled trials. Nutr J 2013; 12:23
22. Zeng T, Guo FF, Zhang CL, Song FY, Zhao XL, Xie KQ. A meta-analysis of randomized, double-blind, placebo-controlled trials for the effects of garlic on serum lipid profiles. J Sci Food Agric 2012; 92:1892- 1902
23. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and val idation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41:1313-1321
24. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalco holic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999; 94:2467-2474
25. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327:557-560
26. Lee YM, Sutedja DS, Wai CT, Dan YY, Aung MO, Zhou L, et al. A randomized controlled pilot study of Pentoxifylline in patients with non-alcoholic steatohepatitis (NASH). Hepatol Int 2008; 2:196-201
27. Buranawati W, Thoun-U-Thaisri P, Pra moolsinsup C, Wisedopas N, Atamasirikul K, Udomsubpayakul U. Pentoxifylline for treatment of nonalcoholic fatty liver disease (NAFLD): a randomized, placebocontrolled study. Thai J Gastroenterol 2007; 8:57-64
28. Amin MA, Sabry D, Kassem M, Amin A. Effect of pentoxifylline on serum hyaluronic acid in patients with non-alcoholic fatty liver disease. Arab J Gastroenterol 2009; 10:102-105
29. Zein CO, Yerian LM, Gogate P, Lopez R, Kirwan JP, Feldstein AE, et al. Pentoxifylline improves nonalcoholic steatohepatitis: a randomized placebocontrolled trial. Hepatology 2011; 54:1610-1619
30. Van Wagner LB, Koppe SW, Brunt EM, Gottstein J, Gardikiotes K, Green RM, et al. Pentoxifylline for the treatment of non-alcoholic steatohepatitis: a randomized controlled trial. Ann Hepatol 2011; 10:277-286
31. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Associa tion for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012; 55:2005-2023
32. Smith BW, Adams LA. Non-alcoholic fatty liver disease. Crit Rev Clin Lab Sci 2011; 48:97-113
33. Dowman JK, Armstrong MJ, Tomlinson JW, Newsome PN. Current therapeutic strategies in non-alcoholic fatty liver disease. Diabetes Obes Metab 2011; 13:692-702
34. Xiao J, Guo R, Fung ML, Liong EC, Tipoe GL. Therapeutic approaches to non-alcoholic fatty liver disease: past achievements and future challenges. Hepatobiliary Panc reat Dis Int 2013; 12:125-135
35. Sterling RK, Sanyal AJ. Pentoxifylline for steatohepatitis: magic bullet or smoking gun Hepatology 2011; 54:1496-1499
36. Mukhopadhy ay S, Hoidal JR, Mukherjee TK. Role of TNFalpha in pulmonary pathophysiology. Respir Res 2006; 7:125
37. Martins AM, Nobre AC, Almeida AC, Bezerra G, Lima AA, Fonteles MC, et al. Thalidomide and pentoxifylline block the renal effects of supernatants of macrophages activated with Crotalus durissus cascavella venom. Braz J Med Biol Res 2004; 37:1525-1530
38. Lin HI, Chu SJ,Wang D, Feng NH. Pharmacological modulation of TNF production in macrophages. J Microbiol Immunol Infect 2004; 37:8-15
39. Tong Z, Chen B, Dai H, Bauer PC, Guzman J, Costabel U. Extrinsic allergic alveolitis: inhibitory effects of pentoxifylline on cytokine production by alveolar macrophages. Ann Allergy Asthma Immunol 2004; 92:234-239
40. Akriviadis E, Botla R, Briggs W, Han S, Reynolds T, Shakil O. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a doubleblind, placebo-controlled trial. Gastroenterology 2000; 119:1637-1648
41. Hepgul G Tanrikulu S Unalp HR Akguner T Erbil Y Olgac V et al, Preventive effect of pentoxifylline on acute radiation damage via antiox idant and anti-inflammatory pathways, Dig Dis Sci, 2010,55, 617-625.
42. Sumida Y, Niki E, Naito Y, Yoshikawa T. Involvement of free radicals and oxidative stress in NAFLD/NASH. Free Radic Res 2013; 47:869-880.